A Clinical trial to study the effect of the drug Megari Chooranam in patients having Madhumegam (Type II Diabetes Mellitus)

Phase II Non-randomised open clinical evaluation of Siddha Medicine Megari Chooranam for the management of Madhumegam (Type II Diabetes Mellitus)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/11/037713

Enrollment

Registered

2021-11-01

Start date

Unknown

Completion date

Unknown

Last updated

2022-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E11- Type 2 diabetes mellitus

Interventions

Intervention1: MEGARI CHOORANAM: 800-1000mg of Megari Chooranam is administered twice a day with luke warm water for 30 days Control Intervention1: NIL: NIL

Eligibility

Inclusion criteria

Inclusion criteria: Subjects with age between 30-60 years Blood glucose(F) - 126 mg/dl to 140 mg/dl Blood glucose(PP) - 180 mg/dl to 280 mg/dl HbA1c - 6.5% to 8% Polyuria Polyphagia Polydipsia Nocturia

Exclusion criteria

Exclusion criteria: Pregnant Women Lactating mothers Insulin dependent Diabetes Mellitus Cardiovascular disease Diabetic nephropathy Diabetic retinopathy T.B affected individuals HbA1c >8%

Design outcomes

Primary

Measure	Time frame
Primary outcome is mainly assessed by reduction in blood sugar and HbA1c Level and reduction in clinical symptomsTimepoint: 30 days	—

Secondary

Measure	Time frame
Secondary outcome is assessed by comparing the safety parameters before and after treatment.Timepoint: 30 days	—

Countries

India

Contacts

Public ContactDr Anbu N

Government Siddha Medical College

nanbu.sumi@gmail.com9443279412

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026